Latest Research And Development News

Hazer Group and First Graphene have signed a non-binding MOU to explore innovative applications for Hazer’s proprietary graphite, aiming to capitalize on rising global demand amid supply constraints.

ALCORE, ABx Group’s subsidiary, has secured government approval for overseas R&D activities and is pursuing a $5 million grant to accelerate its clean fluorine chemical technology commercialisation.

Acrux Limited has received a $3.04 million R&D Tax Incentive rebate for FY25 and fully repaid its short-term funding facility, underscoring its commitment to Australian pharmaceutical innovation.

Firebird Metals has secured a strategic partnership with Kazakhstan-based Taza Metal Technologies to co-fund the development of next-generation manganese-rich battery cathodes, reinforcing its position in the evolving EV materials market.

333D Limited has responded to ASX queries, clarifying that its Bitcoin Treasury Management Policy approval is not price sensitive, while disclosing a $370,500 Bitcoin acquisition funded partly by R&D tax incentives.

4DMedical has bolstered its financial footing with a $6 million R&D tax incentive and a $10 million strategic investment, while its XV LVAS® technology gains clinical validation for predicting serious COPD treatment complications.

Lumos Diagnostics, backed by BARDA, is set to begin a pivotal pediatric clinical study to extend the use of its rapid respiratory infection test, FebriDx, to children aged 2–12 in U.S. CLIA-waived settings, potentially unlocking a $1 billion market.

Netlinkz Limited has reported a significant 43% reduction in net loss for FY25, driven by a strategic exit from China and Japan and a renewed focus on cybersecurity growth in the Philippines through its Securelink Networks joint venture.

Recce Pharmaceuticals reported a 21% increase in net loss to $21.4 million for FY2025, driven by intensified R&D spending. The company secured key regulatory approvals for Phase 3 trials of its lead anti-infective gel and bolstered its financial position with significant capital raises and grants.

Opthea Limited reported a 26% reduction in net loss for FY2025 despite discontinuing its wet AMD drug after failed Phase III trials. The company settled its Development Funding Agreement with investors, securing liquidity and planning a strategic pivot.

Nanoveu Limited’s transformative half-year report highlights its EMASS acquisition, executive hires, and technology advances amid a $3 million loss and new US OTCQB listing.

FBR Ltd reported a 57% revenue increase driven by property sales but posted a $29 million loss as it advances commercialization of its Hadrian X® robotic bricklayer and secures significant new funding.